Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
This research article evaluates the persistence, adherence and healthcare costs among biologic-naive patients receiving apremilast or biologics for the treatment of psoriasis.
Please sign in or register for FREE
Sign in to The Evidence Base®
Did you know?
Your The Evidence Base™ account also gives you access to communities on regenerative medicine, real-world evidence and drug discovery. Find out more>>